REDWOOD CITY, CA, USA I Decemer 02, 2024 I Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...

PARIS, France I 03, 2024 I Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for ...

Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer ...

BIPAVE-001 is a Phase 1/2 trial designed to evaluate the safety, pharmacokinetic, and efficacy of AI-081. The Part A portion is a first-in-human dose escalation study that will determine the ...

PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones – “PTC518 is the leading oral disease-modifying therapy in development for Huntington’s disease and the economics ...

Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over ...

BENGALURU, Karnataka, India I 01, 2024 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE ...

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company’s global footprint expansion. SHANGHAI, China I November 28, 2024 I ...

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of ...

SÖDERTÄLJE, Sweden I November 26, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the submission of its first Clinical Trial Application ...